The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Scientists discover links between Alzheimer’s disease and gut microbiota
Gut-Brain Axis

Scientists discover links between Alzheimer’s disease and gut microbiota

OCT 19, 2023
Kanvas Biosciences Acquires Federation Bio Assets to Scale Discovery, Development and Manufacturing
Clinical & Manufacturing

Kanvas Biosciences Acquires Federation Bio Assets to Scale Discovery, Development and Manufacturing

OCT 12, 2023
Clinical Microbiomics announces merger with CosmosID
Finance

Clinical Microbiomics announces merger with CosmosID

OCT 11, 2023
First Patient Dosed in Phase 2 Clinical Trial of Vedanta’s VE202 for the Treatment of Ulcerative Colitis
Clinical & Manufacturing

First Patient Dosed in Phase 2 Clinical Trial of Vedanta’s VE202 for the Treatment of Ulcerative Colitis

OCT 5, 2023
Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A
Finance

Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A

SEP 28, 2023
New standards in sensitivity and accuracy for microbiome research
Editor's Choice

New standards in sensitivity and accuracy for microbiome research

SEP 20, 2023
MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis
Clinical & Manufacturing

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis

SEP 19, 2023
Protective particles allow engineered probiotics to report gut disease
Biotics and Supplements

Protective particles allow engineered probiotics to report gut disease

SEP 12, 2023
Women’s Health in Microbiome Research
Pharma & Human Health

Women’s Health in Microbiome Research

SEP 5, 2023
Lonza’s Capsugel® Enprotect® capsule for effective enteric delivery
Pharma & Human Health

Lonza’s Capsugel® Enprotect® capsule for effective enteric delivery

AUG 31, 2023
Anti-bacterial virus treated antibiotic resistant infections with 86.6% success rate
Infectious Disease & AMR

Anti-bacterial virus treated antibiotic resistant infections with 86.6% success rate

AUG 24, 2023